Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 5285392, 8 pages
https://doi.org/10.1155/2018/5285392
Research Article

Apelin and Atrial Fibrillation: The Role in the Arrhythmia Recurrence Prognosis

1Intensive Cardiac Therapy Clinic, Medical University, Lodz, Poland
2Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland

Correspondence should be addressed to Agata Salska; moc.liamg@ataga.akslas

Received 7 August 2017; Revised 10 January 2018; Accepted 5 February 2018; Published 12 March 2018

Academic Editor: Zhongjie Shi

Copyright © 2018 Agata Salska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Camm, G. Y. Lip, R. De Caterina et al., “2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association,” European Heart Journal, vol. 33, no. 21, pp. 2719–2747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. S. Go, E. M. Hylek, K. A. Phillips et al., “Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study,” JAMA, vol. 285, no. 18, pp. 2370–2375, 2001. View at Publisher · View at Google Scholar
  3. S. Stewart, C. L. Hart, D. J. Hole, and J. J. V. McMurray, “A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study,” The American Journal of Medicine, vol. 113, no. 5, pp. 359–364, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Gilewski and W. Sinkiewicz, “The electrical cardioversion of atrial fibrillation after 50 years since initial application: contemporary knowledge,” Kardiologia Polska, vol. 71, no. 7, pp. 757–763, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Hijazi, J. Oldgren, A. Siegbahn, C. B. Granger, and L. Wallentin, “Biomarkers in atrial fibrillation: a clinical review,” European Heart Journal, vol. 34, no. 20, pp. 1475–1480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. D. I. Shin, K. Jaekel, P. Schley et al., “Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion,” Zeitschrift für Kardiologie, vol. 94, no. 12, pp. 795–800, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Zografos and D. Katritsis, “Natriuretic peptides as predictors of atrial fibrillation recurrences following electrical cardioversion,” Arrhythmia & Electrophysiology Review, vol. 2, no. 2, pp. 109–114, 2013. View at Publisher · View at Google Scholar
  8. K. Tatemoto, M. Hosoya, Y. Habata et al., “Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor,” Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471–476, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Kleinz and A. P. Davenport, “Emerging roles of apelin in biology and medicine,” Pharmacology & Therapeutics, vol. 107, no. 2, pp. 198–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. O’Carroll, S. J. Lolait, L. E. Harris, and G. R. Pope, “The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis,” The Journal of Endocrinology, vol. 219, no. 1, pp. R13–R35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Chen, E. Ashley, D. Deng et al., “Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction,” Circulation, vol. 108, no. 12, pp. 1432–1439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Boucher, B. Masri, D. Daviaud et al., “Apelin, a newly identified adipokine up-regulated by insulin and obesity,” Endocrinology, vol. 146, no. 4, pp. 1764–1771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. C. C. Cheng, P. Weerateerangkul, Y. Y. Lu et al., “Apelin regulates the electrophysiological characteristics of atrial myocytes,” European Journal of Clinical Investigation, vol. 43, no. 1, pp. 34–40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. P. T. Ellinor, A. F. Low, and C. A. Macrae, “Reduced apelin levels in lone atrial fibrillation,” European Heart Journal, vol. 27, no. 2, pp. 222–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Gurger, A. Celik, M. Balin et al., “The association between apelin-12 levels and paroxysmal supraventricular tachycardia,” Journal of Cardiovascular Medicine, vol. 15, no. 8, pp. 642–646, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. E. M. Kallergis, E. G. Manios, E. M. Kanoupakis et al., “Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation,” The American Journal of Cardiology, vol. 105, no. 1, pp. 90–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Falcone, M. P. Buzzi, A. D’Angelo et al., “Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 3, pp. 917–925, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Tveit, I. Seljeflot, I. Grundvold, M. Abdelnoor, H. Arnesen, and P. Smith, “Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion,” International Journal of Cardiology, vol. 131, no. 2, pp. 234–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Sanna, A. Sonaglioni, M. Pieroni et al., “Baseline NT-pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis,” Indian Pacing and Electrophysiology Journal, vol. 9, no. 1, pp. 15–24, 2009. View at Google Scholar
  20. I. Castan-Laurell, C. Dray, C. Attané, T. Duparc, C. Knauf, and P. Valet, “Apelin, diabetes, and obesity,” Endocrine, vol. 40, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Castan-Laurell, J. Boucher, C. Dray, D. Daviaud, C. Guigné, and P. Valet, “Apelin, a novel adipokine over-produced in obesity: friend or foe?” Molecular and Cellular Endocrinology, vol. 245, no. 1-2, pp. 7–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Przewlocka-Kosmala, T. Kotwica, A. Mysiak, and W. Kosmala, “Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction,” Journal of Hypertension, vol. 29, no. 5, pp. 971–979, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. D. P. Papadopoulos, I. Mourouzis, C. Faselis et al., “Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels,” Journal of Clinical Hypertension, vol. 15, no. 5, pp. 333–336, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. N. P. E. Kadoglou, S. Lampropoulos, A. Kapelouzou et al., “Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY,” Translational Research, vol. 155, no. 5, pp. 238–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Li, Y. Bai, and J. Hu, “Reduced apelin levels in stable angina,” Internal Medicine, vol. 47, no. 22, pp. 1951–1955, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. S. Chong, R. S. Gardner, J. J. Morton, E. A. Ashley, and T. A. McDonagh, “Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure,” European Journal of Heart Failure, vol. 8, no. 4, pp. 355–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Telejko, M. Kuzmicki, N. Wawrusiewicz-Kurylonek et al., “Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 87, no. 2, pp. 176–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Y. Ma, T. Y. Yu, J. N. Wei et al., “Plasma apelin: a novel biomarker for predicting diabetes,” Clinica Chimica Acta, vol. 435, pp. 18–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. N. P. E. Kadoglou, H. Tsanikidis, A. Kapelouzou et al., “Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus,” Metabolism, vol. 59, no. 3, pp. 373–379, 2010. View at Publisher · View at Google Scholar · View at Scopus